

2. (Amended) The system according to claim 1, wherein the bindable epitope of the target polypeptide is capable of being removed.

3. (Amended) The system according to claim 2, wherein the first binding moiety of the multivalent binding polypeptide is capable of removing the bindable epitope.

4. (Amended) The system according to claim 2, wherein the system further comprises:
a second transgenically produced multivalent binding polypeptide comprising a first catalytic domain and a second binding moiety which specifically is capable of binding a matrix, wherein the catalytic domain is capable of removing the bindable epitope of the target polypeptide; and

a second matrix which specifically is capable of binding the second binding moiety of the second transgenically produced multivalent binding polypeptide, wherein the matrix is different than the matrix specifically bound by the second binding moiety of the first transgenic multivalent binding polypeptide.

5. (Amended) A method of obtaining a target polypeptide having a bindable epitope from a product, the method comprising:

contacting a product which comprises a target polypeptide having a bindable epitope with a transgenically produced multivalent binding polypeptide, wherein the transgenically produced multivalent binding polypeptide comprises a first binding moiety which specifically binds the bindable epitope of the target polypeptide and a second binding moiety which specifically binds a matrix, to thereby provide a reaction mixture;

contacting the reaction mixture with a matrix which specifically binds the second binding moiety of the multivalent binding polypeptide; and

removing reaction mixture which does not bind to the matrix, to thereby obtain the target polypeptide from the product.

6. (Reiterated) The method according to claim 5, further comprising eluting the target polypeptide from the matrix.

8. (Reiterated) The method according to claim 5, wherein the target polypeptide is an antibody.

9. (Amended) The method according to claim 8, wherein the first binding moiety of the transgenic multivalent binding polypeptide is protein L or a functional fragment thereof.

10. (Amended) The method according to claim 9, wherein the second binding moiety of the transgenic multivalent binding polypeptide is a cellulose bind domain (CBD) or a functional fragment thereof.

12. (Amended) A method of obtaining a target polypeptide having a bindable epitope from milk of a non-human transgenic mammal, the method comprising:

contacting milk which comprises a target polypeptide having a bindable epitope with a transgenically produced multivalent binding polypeptide, wherein the multivalent binding polypeptide comprises a first binding moiety which specifically binds the bindable epitope of the target polypeptide and a second binding moiety which specifically binds a matrix, to thereby provide a reaction mixture;

contacting the reaction mixture with a matrix which specifically binds the second binding moiety of the multivalent binding polypeptide; and

removing reaction mixture which does not bind to the matrix, to thereby obtain the target polypeptide from the milk.

13. (Reiterated) The method according to claim 12, further comprising eluting the target polypeptide from the matrix.

14. (Reiterated) The method of claim 12, wherein the target polypeptide is a transgenically produced polypeptide.

B4 15. (Amended) The method according to claim 12, wherein the transgenically produced multivalent binding polypeptide is produced in milk from another non-human transgenic mammal.--

Please add claims 19-30.

B 19. (New) The system according to claim 2, wherein the transgenically produced multivalent polypeptide further comprises a third binding moiety and the third binding moiety is capable of removing the bindable epitope from the target polypeptide.

20. (New) The method according to claim 5, wherein the transgenically produced multivalent polypeptide further comprises a third binding moiety and the third binding moiety is capable of removing the bindable epitope from the target polypeptide.

21. (New) The method of claim 5, wherein the first binding moiety of the multivalent binding polypeptide is an antibody or functional fragment thereof which binds the bindable epitope of the target polypeptide.

22. (New) The method of claim 5, wherein the second binding moiety of the multivalent binding polypeptide is a cellulose binding domain (CBD), or a functional fragment thereof.

23. (New) The method of claim 5, wherein the target polypeptide is a receptor and the first binding moiety of the multivalent binding polypeptide is a ligand which binds the bindable epitope of the receptor.

24. (New) The method of claim 5, wherein the first binding moiety of the multivalent binding polypeptide is a receptor which binds the bindable epitope of the target polypeptide.

25. (New) The method according to claim 12, wherein the transgenically produced multivalent binding polypeptide is produced in the milk of the non-human transgenic mammal.

26. (New) The method of claim 12, wherein the transgenically produced multivalent polypeptide further comprises a third binding moiety and the third binding moiety is capable of removing the bindable epitope from the target polypeptide.

27. (New) The method of claim 12, wherein the first binding moiety of the multivalent binding polypeptide is an antibody or functional fragment thereof which binds the bindable epitope of the target polypeptide.

28. (New) The method of claim 12, wherein the second binding moiety of the multivalent binding polypeptide is a cellulose binding domain (CBD), or a functional fragment thereof.

29. (New) The method of claim 12, wherein the target polypeptide is a receptor and the first binding moiety of the multivalent binding polypeptide is a ligand which binds the bindable epitope of the receptor.

30. (New) The method of claim 12, wherein the first binding moiety of the multivalent binding polypeptide is a receptor which binds the bindable epitope of the target polypeptide. --

In the drawings:

Please substitute Figure 1, Figure 2, and Figure 3 with the new formalized Figure 1, Figure 2, and Figure 3.